Synlett 2021; 32(14): 1469-1472
DOI: 10.1055/s-0040-1720348
letter

Efficient Construction of (±)-epi-Costunolide through a Chromium(II)-Mediated Nozaki–Hiyama–Kishi Reaction

Weichen Dai
a   Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. of China
b   Hanlin College, Nanjing University of Chinese Medicine, Taizhou 225300, P. R. of China
,
Jie Zheng
a   Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. of China
,
Xinyu Yan
a   Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. of China
,
Wei Tang
c   Pharmaron (Ningbo) Technology Development Co., Ltd, Ningbo, 315336, P. R. of China
,
Lihong Hu
a   Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. of China
,
Yinan Zhang
a   Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. of China
› Author Affiliations
This work was supported by the National Natural Science Foundation of China (grants: 21877062, YZ; 81803342, LH), the key research projects of Jiangsu Higher Education (No. 18KJA360010, YZ), and the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant: 18KJD360001).
 


Abstract

(±)-epi-Costunolide has been synthesized through a seven-step procedure starting from (E,E)-farnesol. The key step includes an intramolecular allylation of an aldehyde through a chromium(II)-mediated Nozaki–Hiyama–Kishi reaction, in which more than one equivalent of CrCl2 has been recognized as the most effective reagent to promote the conversion. An anti-inflammatory screen showed that epi-costunolide is a moderate inhibitor of B lymphocyte proliferation.


#

Costunolide is a germacrene sesquiterpene lactone isolated from the herbal preparation radix aucklandiae, obtained from the roots of Saussurea costus (formerly Aucklandia lappa Decne), that shows a wide variety of pharmacological activities including antiinflammatory,[1] antibacterial,[2] and antitumor properties.[3] Costunolide has a ten-membered-ring skeleton fused to a trans α-methylene γ-lactone at the C6 and C7 positions. Owing to its simple structure and unique activities, costunolide has received much attention from the synthetic and medicinal communities. Although its structural modifications and structure–activity relationship have been extensively studied,[4] only a few synthetic approaches have focused on the construction of the germacrene scaffold. The challenges mostly lie in (1) the formation of a medium-sized ring, (2) stereochemical control, and (3) structurally sensitivity to both acidic and basic conditions.

The first total synthesis was carried out by Grieco and Nishizawa,[5] who employed α-santonin as the starting material and a Cope sigmatropic rearrangement to expand to the ten-membered ring (Scheme [1a]). In contrast, Takahashi et al. contracted a 13-membered cyclic ether ring through a [2,3]-Wittig rearrangement to afford a germacrene scaffold (Scheme [1b]).[6] Another synthesis by Yang et al.[7] featured an aldol addition of chiral camphorsultam derivative to an α,β-unsaturated aldehyde (Scheme [1c]). Refunctionalization, C8–C9 intramolecular alkylation, and oxidative lactonization gave costunolide in a total of 13 reaction steps. The most efficient synthetic strategy came from a bioinspired cyclization of an aldehyde and allylic halide, which included a Nozaki–Hiyama–Kishi (NHK) reaction or a Barbier reaction developed by Hirotaka et al.,[8] and by Corey and Reddy,[9] respectively (Scheme [1d]). The configuration of the anti-adduct was controlled by a Zimmerman–Traxler transition state. However, further conversions into the γ-lactone still required an allylic oxidation involving highly flammable t-BuLi and an extra esterification. Toward this end, we have developed an efficient strategy for the construction of the germacrene scaffold and the corresponding total synthesis of (±)-epi-costunolide. This synthetic method sets the stage for future in-depth structure–activity relationship studies and mechanistic investigations of this fascinating natural product.

Zoom Image
Scheme 1 Reported syntheses of costunolide

Our initial intent was to utilize the lactone ring with a preassembled ester group on the farnesol chain. Compared with the existing strategy, our current retrosynthetic format features a tandem allylation reaction and a lactonization to give costunolide in a one-pot procedure (Scheme [2]). The ester intermediate 1 might be obtained by an allylic SN′ substitution and a Baylis–Hillman reaction from aldehyde 3, which, in turn, could be simply obtained by direct oxidation from (E,E)-farnesol.

Zoom Image
Scheme 2 Retrosynthetic analysis of costunolide synthesis

Since the key step is the tandem allylation and lactonization, we attempted a template reaction between 3-methylcrotonaldehyde (5) and the Baylis–Hillman ester 6. First, we screened the general conditions previously studied for either the Barbier or the NHK reaction (Table [1]). To our delight, more than one equivalent of CrCl2 in DMF gave the syn-product 7 in 82% yield (Table [1], entry 1). However, none of the corresponding product was detected when chromium(II) was generated in situ with LiAlH4 (entry 2). Note that a catalytic amount of CrCl2 with Mn(0)[10] also gave the desired product, albeit in a low yield (entry 3). Since the NHK reaction did not directly give the anti-lactone product, we next tried several standard conditions for the Barbier reaction. Zero-valent metals such as In,[11] Zn,[12] or Zn–Cu[12] afforded the syn-lactone product 8 in good to moderate yields (entries 4–6). Unfortunately, an extensive search of conditions showed that no metal exclusively gave the desired anti-lactone product 9 in a satisfactory yield (entries 7 and 8). Other conditions with various Sn salts failed to give the desired product (entry 9).[13]

Table 1 Optimization of a Template Carbonyl Allylationa

Entry

Conditions

Equiv

Solvent

Temp (℃)

Time (h)

Product

Yieldb (%)

1

CrCl2

7

DMF

rt

5

7

82

2

CrCl3/LiAlH4

8/4

DMF

rt

5

c

3

CrCl2/Mn

0.1/2

DMF

rt

8

7

8

4

In

2

DMF

rt

4

8

56

5

Zn

6

THF

65

10

8

51

6

Zn–Cu

6

THF

rt

1

8

79

7

SnCl2/KI

1.5/1.5

THF

rt

18

8, 9

16, 25d

8

Sn

2

THF–aq NH4Cl (2:1)

60

12

7, 8, 9

20, 7, 13d

9

SnCl4/TBAI

2/6

CH2Cl2

rt

48

e

a All reactions were conducted under an argon atmosphere. 3-Methylcrotonaldehyde (5) reacted with the Baylis–Hillman ester 6 in a ratio of 1:2; see the Supporting Information for details.

b Isolated yield unless specified.

c Decomposition of the starting material.

d 8 and 9 were inseparable by silica gel chromatography, and their yields were determined by 1H NMR spectroscopy of the mixture.

e No product was detected.

A plausible mechanism for the metal-mediated carbonyl allylation is proposed in Figure [1]. Initially, a metal–halogen exchange activates the Baylis–Hillman ester 6, and the activated ester undergoes coordination to the acrylate 5. The (Z)-allyl intermediate that produces the syn-product adopts a chair transition state, whereas the formation of the (E)-allyl intermediate requires a boat transition state, which hinders the production of the anti-product. Tin could have produced a mixture of syn- and anti-products as a result of instability of the allyltin toward ZE isomerization.[14]

Zoom Image
Figure 1 A plausible mechanism for the carbonyl allylation.

With the optimal conditions for the allylation in hand, we made a further attempt at a total synthesis (Scheme [3]) starting with TBDPS protection and epoxidation of (E,E)-farnesol on a gram scale (49% overall yield). Periodate oxidation of 4 afforded the desired aldehyde 3 in an excellent yield. Note that a TBS protective group was not stable to periodate oxidation, whereas TBDPS survived this. Use of the standard Baylis–Hillman conditions successfully added the acrylate moiety to the scaffold, which was converted into the allylic bromide 10 in the presence of PPh3 and CBr4. The precursor 1 was obtained by Dess–Martin oxidation after removal of the TBDPS group in a HF/pyridine medium. The overall yield of this five-step conversion was, remarkably, as high as 24%.

Zoom Image
Scheme 3 Synthesis of precursor 1. Reagents and conditions: (a) (i) TBDPSCl, imidazole, CH2Cl2; (ii) NBS, THF–H2O (3:1); (iii) K2CO3, MeOH; 49% for three steps; (b) H5IO6, NaIO4, THF–H2O (4:1), 95%; (c) methyl acrylate, DABCO, MeOH, 81%; (d) CBr4, Ph3P, DIPEA, CH2Cl2, 86%; (e) (i) HF–pyridine, THF, 84%; (ii) Dess–Martin periodinane, CH2Cl2, 87%.

By using our optimized conditions, precursor 1 was treated with CrCl2 in DMF to give the homoallylic alcohol syn-product 11 in a comparable yield to that of the NHK template reaction.[15] However, zero-valent metals under Barbier conditions decomposed compound 1 and failed to deliver the desired lactone product directly under the optimal reaction conditions (Table [2]). Finally, an intramolecular cyclization was carried out with DBU to give (±)-epi-costunolide 12, the relative configuration of which was revealed by NOE spectroscopy (see the Supporting Information). Note also that Massanet’s group previously obtained epi-costunolide by a semi-synthesis from natural costunolide;[16] however, our method is based on an ab initio synthetic route.

Table 2 Completion of the (±)-epi-Costunolide (12) Synthesisa

Entry

Conditions

Equiv

Solvent

Temp (℃)

Time (h)

Yieldb (%) of 11

1

CrCl2

7

DMF

rt

3

76

2

In

2

DMF

rt

5

c

3

Zn

6

THF

65

10

c

4

Zn–Cu

6

THF

rt

10

c

a All reactions were conducted under an argon atmosphere; see the Supporting Information for details.

b Isolated yield.

c Decomposition of compound 1.

Biological studies showed that the epimer (IC50: 9.7 ± 0.78 μM) had a weaker antiinflammatory effect than natural costunolide (IC50: 1.2 ± 0.19 μM) in inhibiting B lymphocyte proliferation.

In summary, a robust and effective route including a key intramolecular cyclization reaction with CrCl2 readily afforded (±)-epi-costunolide. Starting from (E,E)-farnesol, this is the simplest synthetic route to date for constructing a germacrane sesquiterpene lactone, requiring only seven steps and giving a 12% total yield. Considering its high stereoselectivity, the chromium(II)-mediated NHK reaction has proven to be a convenient method for the synthesis of further analogues of use in a medicinal perspective; these are under development in our laboratory and will be reported in due course.


#

Conflict of Interest

The authors declare no conflict of interest.

Supporting Information

  • References and Notes

    • 1a Scarponi C, Butturini E, Sestito R, Madonna S, Cavani A, Mariotto S, Albanesi C. PLoS One 2014; 9: e107904
    • 1b Zheng H, Chen Y, Zhang J, Wang L, Jin Z, Huang H, Man S, Gao W. Chem.–Biol. Interact. 2016; 250: 68
    • 2a Luna-Herrera J, Costa M, González H, Rodrigues A, Castilho P. J. Antimicrob. Chemother. 2007; 59: 548
    • 2b Park J.-B, Lee C.-K, Park H.-J. Arch. Pharmacal Res 1997; 20: 275
    • 2c Duraipandiyan V, Al-Harbi NA, Ignacimuthu S, Muthukumar C. BMC Complementary Altern. Med. 2012; 12: 13
    • 3a Bocca C, Gabriel L, Bozzo F, Miglietta A. Chem.–Biol. Interact. 2004; 147: 79
    • 3b Cai H, He X, Yang C. Phytother. Res. 2018; 32: 1764
    • 3c Dong G.-Z, Shim A.-R, Hyeon JS, Lee HJ, Ryu J.-H. Phytother. Res. 2015; 29: 680
    • 3d Hsu J.-L, Pan S.-L, Ho Y.-F, Hwang T.-L, Kung F.-L, Guh J.-H. J. Urol (N. Y., NY U. S.) 2011; 185: 1967
    • 3e Liu C.-Y, Chang H.-S, Chen I.-S, Chen C.-J, Hsu M.-L, Fu S.-L, Chen Y.-J. Radiat. Oncol. 2011; 6: 56
    • 4a Macías FA, Galindo JC. G, Massanet GM. Phytochemistry 1992; 31: 1969
    • 4b Barrero AF, Oltra JE, Cuerva JM, Rosales A. J. Org. Chem. 2002; 67: 2566
    • 4c Macías FA, Velasco RF, Álvarez JA, Castellano D, Galindo JC. G. Tetrahedron 2004; 60: 8477
    • 4d Srivastava SK, Abraham A, Bhat B, Jaggi M, Singh AT, Sanna VK, Singh G, Agarwal SK, Mukherjee R, Burman AC. Bioorg. Med. Chem. Lett. 2006; 16: 4195
    • 4e Vadaparthi PR. R, Kumar CP, Kumar K, Venkanna A, Nayak VL, Ramakrishna S, Babu KS. Med. Chem. Res. 2015; 24: 2871
  • 5 Grieco PA, Nishizawa M. J. Org. Chem. 1977; 42: 1717
  • 6 Takahashi T, Nemoto H, Kanda Y, Tsuji J, Fujise Y. J. Org. Chem. 1986; 51: 4315
  • 7 Yang Z.-J, Ge W.-Z, Li Q.-Y, Lu Y, Gong J.-M, Kuang B.-J, Xi X, Wu H, Zhang Q, Chen Y. J. Med. Chem 2015; 58: 7007
  • 8 Hirotaka S, Kazuyoshi O, Keiko K, Kazuyuki H, Nobutoshi M, Isao K. Chem. Lett. 1986; 85
  • 9 Reddy DS, Corey EJ. J. Am. Chem. Soc. 2018; 140: 16909
  • 10 Fürstner A, Shi N. J. Am. Chem. Soc 1996; 118: 12349
  • 11 Bryan VJ, Chan T.-H. Tetrahedron Lett. 1996; 37: 5341
  • 12 Semmelhack MF, Wu ES. C. J. Am. Chem. Soc 1976; 98: 3384
  • 13 Masuyama Y, Suga T, Watabe A, Kurusu Y. Tetrahedron Lett 2003; 44: 2845
    • 14a Verdone JA, Mangravite JA, Scarpa NM, Kuivila HG. J. Am. Chem. Soc 1975; 97: 843
    • 14b Matarasso-Tchiroukhine E, Cadiot P. J. Organomet. Chem. 1976; 121: 155
  • 15 Intramolecular Allylation of Compound 1A solution of the aldehyde 1 (94 mg, 0.273 mmol) in anhyd DMF (2.5 mL) was added to a solution of CrCl2 (235 mg, 1.9 mmol) in anhyd DMF (12 mL) at rt under Ar. The mixture was stirred for 3 h and then the reaction was quenched with H2O (8 mL). The mixture was extracted with EtOAc, and the combined organic layers were washed with brine, dried (Na2SO4), and concentrated under a reduced pressure. The residue was purified by column chromatography (silica gel, 5% EtOAc–hexane) to give 11 as a colorless oil; yield: 54.5 mg (0.208 mmol, 76%).1H NMR (500 MHz, CDCl3): δ = 6.36–6.29 (m, 1 H), 5.78–5.74 (m, 1 H), 5.13–4.98 (m, 2 H), 4.41–4.40 (m, 1 H), 3.80 (s, 3 H), 2.76–2.52 (m, 2 H), 2.43–2.33 (m, 2 H), 2.22–2.19 (m, 1 H), 2.13 (d, J = 9.3 Hz, 3 H), 2.02–1.84 (m, 1 H), 1.78–1.69 (m, 2 H), 1.59 (s, 3 H), 1.44–1.40 (m, 1 H). 13C NMR (125 MHz, CDCl3): δ = 168.7, 142.7, 138.7, 137.4, 126.7, 124.3, 122.1, 70.3, 52.2, 44.3, 40.0, 37.3, 34.9, 25.6, 21.0, 17.0. HRMS (ESI-TOF): m/z [M + Na]+ calcd for C16H24NaO3: 287.1623; found: 287.1618
  • 16 Azarken R, Guerra FM, Moreno-Dorado FJ, Jorge ZD, Massanet GM. Tetrahedron 2008; 64: 10896

Corresponding Authors

Lihong Hu
Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine
Nanjing, 210023
P. R. of China   
Yinan Zhang
Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine
Nanjing, 210023
P. R. of China   

Publication History

Received: 07 June 2021

Accepted after revision: 25 June 2021

Article published online:
13 July 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References and Notes

    • 1a Scarponi C, Butturini E, Sestito R, Madonna S, Cavani A, Mariotto S, Albanesi C. PLoS One 2014; 9: e107904
    • 1b Zheng H, Chen Y, Zhang J, Wang L, Jin Z, Huang H, Man S, Gao W. Chem.–Biol. Interact. 2016; 250: 68
    • 2a Luna-Herrera J, Costa M, González H, Rodrigues A, Castilho P. J. Antimicrob. Chemother. 2007; 59: 548
    • 2b Park J.-B, Lee C.-K, Park H.-J. Arch. Pharmacal Res 1997; 20: 275
    • 2c Duraipandiyan V, Al-Harbi NA, Ignacimuthu S, Muthukumar C. BMC Complementary Altern. Med. 2012; 12: 13
    • 3a Bocca C, Gabriel L, Bozzo F, Miglietta A. Chem.–Biol. Interact. 2004; 147: 79
    • 3b Cai H, He X, Yang C. Phytother. Res. 2018; 32: 1764
    • 3c Dong G.-Z, Shim A.-R, Hyeon JS, Lee HJ, Ryu J.-H. Phytother. Res. 2015; 29: 680
    • 3d Hsu J.-L, Pan S.-L, Ho Y.-F, Hwang T.-L, Kung F.-L, Guh J.-H. J. Urol (N. Y., NY U. S.) 2011; 185: 1967
    • 3e Liu C.-Y, Chang H.-S, Chen I.-S, Chen C.-J, Hsu M.-L, Fu S.-L, Chen Y.-J. Radiat. Oncol. 2011; 6: 56
    • 4a Macías FA, Galindo JC. G, Massanet GM. Phytochemistry 1992; 31: 1969
    • 4b Barrero AF, Oltra JE, Cuerva JM, Rosales A. J. Org. Chem. 2002; 67: 2566
    • 4c Macías FA, Velasco RF, Álvarez JA, Castellano D, Galindo JC. G. Tetrahedron 2004; 60: 8477
    • 4d Srivastava SK, Abraham A, Bhat B, Jaggi M, Singh AT, Sanna VK, Singh G, Agarwal SK, Mukherjee R, Burman AC. Bioorg. Med. Chem. Lett. 2006; 16: 4195
    • 4e Vadaparthi PR. R, Kumar CP, Kumar K, Venkanna A, Nayak VL, Ramakrishna S, Babu KS. Med. Chem. Res. 2015; 24: 2871
  • 5 Grieco PA, Nishizawa M. J. Org. Chem. 1977; 42: 1717
  • 6 Takahashi T, Nemoto H, Kanda Y, Tsuji J, Fujise Y. J. Org. Chem. 1986; 51: 4315
  • 7 Yang Z.-J, Ge W.-Z, Li Q.-Y, Lu Y, Gong J.-M, Kuang B.-J, Xi X, Wu H, Zhang Q, Chen Y. J. Med. Chem 2015; 58: 7007
  • 8 Hirotaka S, Kazuyoshi O, Keiko K, Kazuyuki H, Nobutoshi M, Isao K. Chem. Lett. 1986; 85
  • 9 Reddy DS, Corey EJ. J. Am. Chem. Soc. 2018; 140: 16909
  • 10 Fürstner A, Shi N. J. Am. Chem. Soc 1996; 118: 12349
  • 11 Bryan VJ, Chan T.-H. Tetrahedron Lett. 1996; 37: 5341
  • 12 Semmelhack MF, Wu ES. C. J. Am. Chem. Soc 1976; 98: 3384
  • 13 Masuyama Y, Suga T, Watabe A, Kurusu Y. Tetrahedron Lett 2003; 44: 2845
    • 14a Verdone JA, Mangravite JA, Scarpa NM, Kuivila HG. J. Am. Chem. Soc 1975; 97: 843
    • 14b Matarasso-Tchiroukhine E, Cadiot P. J. Organomet. Chem. 1976; 121: 155
  • 15 Intramolecular Allylation of Compound 1A solution of the aldehyde 1 (94 mg, 0.273 mmol) in anhyd DMF (2.5 mL) was added to a solution of CrCl2 (235 mg, 1.9 mmol) in anhyd DMF (12 mL) at rt under Ar. The mixture was stirred for 3 h and then the reaction was quenched with H2O (8 mL). The mixture was extracted with EtOAc, and the combined organic layers were washed with brine, dried (Na2SO4), and concentrated under a reduced pressure. The residue was purified by column chromatography (silica gel, 5% EtOAc–hexane) to give 11 as a colorless oil; yield: 54.5 mg (0.208 mmol, 76%).1H NMR (500 MHz, CDCl3): δ = 6.36–6.29 (m, 1 H), 5.78–5.74 (m, 1 H), 5.13–4.98 (m, 2 H), 4.41–4.40 (m, 1 H), 3.80 (s, 3 H), 2.76–2.52 (m, 2 H), 2.43–2.33 (m, 2 H), 2.22–2.19 (m, 1 H), 2.13 (d, J = 9.3 Hz, 3 H), 2.02–1.84 (m, 1 H), 1.78–1.69 (m, 2 H), 1.59 (s, 3 H), 1.44–1.40 (m, 1 H). 13C NMR (125 MHz, CDCl3): δ = 168.7, 142.7, 138.7, 137.4, 126.7, 124.3, 122.1, 70.3, 52.2, 44.3, 40.0, 37.3, 34.9, 25.6, 21.0, 17.0. HRMS (ESI-TOF): m/z [M + Na]+ calcd for C16H24NaO3: 287.1623; found: 287.1618
  • 16 Azarken R, Guerra FM, Moreno-Dorado FJ, Jorge ZD, Massanet GM. Tetrahedron 2008; 64: 10896

Zoom Image
Scheme 1 Reported syntheses of costunolide
Zoom Image
Scheme 2 Retrosynthetic analysis of costunolide synthesis
Zoom Image
Figure 1 A plausible mechanism for the carbonyl allylation.
Zoom Image
Scheme 3 Synthesis of precursor 1. Reagents and conditions: (a) (i) TBDPSCl, imidazole, CH2Cl2; (ii) NBS, THF–H2O (3:1); (iii) K2CO3, MeOH; 49% for three steps; (b) H5IO6, NaIO4, THF–H2O (4:1), 95%; (c) methyl acrylate, DABCO, MeOH, 81%; (d) CBr4, Ph3P, DIPEA, CH2Cl2, 86%; (e) (i) HF–pyridine, THF, 84%; (ii) Dess–Martin periodinane, CH2Cl2, 87%.